Economic Burden of Dermatologic Adverse Events Induced by Molecularly Targeted Cancer Agents
Economic Burden of Dermatologic Adverse Events Induced by Molecularly Targeted Cancer Agents
复制标题
DOI：
10.1001/archdermatol.2011.719
复制
发表时间：
2011-12-01
影响因子：
--
通讯作者：
Lacouture, Mario E.
中科院分区：
文献类型：
--
作者：
Borovicka, Judy H.;Calahan, Cara;Lacouture, Mario E.
目的：报告在接受靶向抗癌治疗的患者中发生的皮肤毒性（dTs）的诊断和治疗的财务影响。设计：单中心回顾性和前瞻性病历数据提取。单位：伊利诺斯州芝加哥西北大学皮肤科。患者：在2005年11月1日至2008年6月30日期间就诊的132名成年人，他们被诊断患有1种原发性癌症，并接受了1种分子靶向药物治疗。主要结果测量：患者在dt相关药物、诊所就诊、实验室和诊断测试以及治疗程序方面的标准计费费用。结果：132例患者接受dT治疗的中位就诊次数为3次，每位患者的中位费用为1920美元。索拉非尼与每位患者最昂贵的总中位成本相关（每位患者2509美元），伊马替尼与每位患者最便宜的总中位成本相关（每位患者1263美元）。在7种靶向药物和所有10种dT中，最昂贵的dT（以药物治疗费用衡量）是手/足皮肤反应，与索拉非尼治疗相关（中位成本，每位患者968美元）（P < 0.001）。第二昂贵的dT是帕尼单抗相关的痘样疹（平均成本，每位患者933美元）（P < 0.001）。结论：与靶向药物相关的dTs的诊断和治疗费用增加了癌症治疗的总体经济负担。努力预防dTs可能对减轻肿瘤学的经济负担很重要。
Objective: To report the financial impact of diagnosing and treating the dermatologic toxicities (dTs) that develop in patients receiving targeted anticancer therapies.Design: Single-center retrospective and prospective medical record data extraction.Setting: Department of Dermatology, Northwestern University, Chicago, Illinois. Patients: One hundred thirty-two adults who presented between November 1, 2005, and June 30, 2008, and who were diagnosed as having 1 primary cancer type and were treated with 1 molecularly targeted agent.Main Outcome Measure: Standard billable costs to the patient for dT-related medications, clinic visits, laboratory and diagnostic testing, and therapeutic procedures.Results: The 132 patients had a median of 3 clinic visits for dT management with a median cost of $1920 per patient. Sorafenib was associated with the most costly overall median cost per patient ($2509 per patient), and imatinib was associated with the least costly overall median cost per patient ($1263 per patient). Among the 7 targeted drugs and all 10 dTs, the most costly dT (measured by cost of treatment with medications) was hand/foot skin reaction, associated with sorafenib therapy (median cost, $968 per patient) (P < .001). The second most costly dT was panitumumab-associated acneiform eruption (median cost, $933 per patient) (P < .001).Conclusion: The cost of diagnosis and treatment of dTs associated with targeted agents contributes to the overall economic burden of cancer care. Efforts toward the prevention of dTs may be important for decreasing the financial burden in oncology.